Sunao Manabe President and COO Glenn Gormley MD PhD Senior Executive Officer Global Head of R&D PLAY LIST from the beginning Top Management Presentation Financial Results of FY2017 Q2 (April 1 - September 30, 2017) Forward-Looking Statements Agenda FY2017 Q2 Financial Results Overview of FY2017 Q2 Results Revenue Operating Profit Special Items Profit Attributable to Owners of the Company Revenue: Major Business Units (incl. Forex Impact) Revenue: Major Products in Japan FY2017 Revised Consolidated Forecast FY2017 Revised Consolidated Forecast Major Management Topics Direct Oral Anticoagulant (DOAC) Market DOAC Market in Japan and Germany Lixiana: Growth in Japan(1) Lixiana: Growth in Japan(2) Lixiana: Growth in Germany and South Korea Major Management Topics [US Pain Business] Changes in US Pain Business DSI: Commitments in Pain Care Three Pain Management Products in US Major Management Topics [Japan Business] VIMPAT: Additional Indication and Lift of Prescription Period Restriction VIMPAT: New Options for Epilepsy Medication CANALIA Combination Tablet: Launched in Sep. 2017 Expansion of Product Portfolio in Japan Shareholder Returns Shareholder Returns R&D Update Agenda R&D Focus and Efficiency R&D Focus and Efficiency DS-8201 Update U3-1402 Update DS-8201: P1 Study Part 2d Result DS-8201: P1 Study Part 2d Patient Demographics DS-8201: P1 Study Part 2d Efficacy (6.4mg/kg) DS-8201: P1 Study Part 2d Efficacy DS-8201: P1 Study Part 2d CT Imaging DS-8201: Part 1 to Part 2 Safety Profile DS-8201: P1 Study Safety - TEAE, any grade, >20% DS-8201: P1 Study Part 2d Conclusions DS-8201: Development Plan U3-1402: Development Plan New Projects Entered to Clinical Phase DS-1205: AXL Inhibitor Summary DS-1205: Results of Pharmacology Study New Collaboration in Oncology Maximize ADC Technology: Collaboration with Glycotope Collaboration with MD Anderson Cancer Center Target DS Compounds and Image of Collaboration Oncology Future Data Disclosure Esaxerenone/CS-3150 Update Mineralocorticoid Receptor Related Hypertension and Diabetic Nephropathy Esaxerenone/CS-3150: P3 Study FY2017 Major R&D Milestone Events (1) FY2017 Major R&D Milestone Events (2) DS R&D Day 2017 Contact address regarding this material Appendix Major R&D Pipeline DS-8201: HER2 Positive Breast Cancer Pivotal P2 Study (JP/US/EU) DS-8201: HER2 Positive Gastric Cancer Pivotal P2 Study (JP/Asia) DS-8201: P1b Nivolumab Combination Study (US/EU) U3-1402: HER3 Positive Breast Cancer P1/2 Study (JP) U3-1402: EGFRm NSCLC P1 Study (US) DS-1205: FIH P1 Osimertinib Combination Study (US) CS-3150: Diabetic Nephropathy P3 Study (ESAX-DN Study) (JP) Abbreviations Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Q&A 8 Q&A 9 Q&A 10 Back Next